Biotalys has completed a pilot production campaign for EVOCA NG, its first commercial biofungicide candidate.
The campaign ran with 21st.BIO, a precision fermentation technology provider. It covered five consecutive production batches. Biotalys says the batches showed that its manufacturing process is consistent and scalable.
The company also reports a more than 15-fold improvement in production efficiency compared with EVOCA, its first-generation product. The campaign produced material and process validation data. That data will support product registration activities.
EVOCA NG is built on AGROBODY, Biotalys’ protein-based technology platform. It is designed to help fruit and vegetable growers control Botrytis, known as grey mold, and powdery mildew. Biotalys plans to register the product in the U.S. and E.U. in 2029. The company puts the combined market at about USD 1.1 billion.
EVOCA NG has the same bioactive ingredient as EVOCA. The U.S. Environmental Protection Agency approved EVOCA in December 2025. Florida and California granted state approval in 2026. In the E.U., the review is still ongoing. The European Food Safety Authority is expected to finish it by the end of this year or early next year, after Biotalys submitted additional data.
Biotalys expects a shorter regulatory path for EVOCA NG. It plans to use equivalency or amendment procedures in both markets.
Chief Executive Officer Carlo Boutton called the result a key step in moving EVOCA NG from development to commercialisation. He said five straight batches show the process is robust and reproducible. Next, the company plans to scale up production with contract manufacturing organisations.


